Recent Datroway and Trodelvy updates provide a favorable read-through to Kelun-Biotech’s sac-TMT. In NSCLC, Datroway’s key Ph3 readouts in 1L NSCLC are concentrated in 1H27. Trodelvy’s US$2bn annualized run rate validates the commercial potential of the TROP2 ADC class, with upcoming ASCENT-GYN readout offering an important read-across in endometrial cancer (EC). Meanwhile, the industry-wide move to combine ADCs with PD-(L)1/VEGF bsAb supports sac-TMT’s combination strategy. With the first positive global Ph3 readout from the TroFuse program, continued data readouts from 18 ongoing global Ph3 trials, MSD’s expanding development strategy, and positive China Ph3 results in first-line NSCLC across the PD-L1 spectrum, we believe sac-TMT remains strongly positioned competitively. We maintain BUY rating on Kelun Biotech with a target price of HK$645.62.
Attention on Datroway’s Ph3 readouts in 1L NSCLC in 1H27. In NSCLC, despite its earlier setback in 2L+ disease, Datroway has four Ph3 readouts expected in 1H27, including three in 1L NSCLC (AVANZAR and TROPIONLung07/- Lung08) and one in 2L EGFR-mutant NSCLC, with the AVANZAR readout being pushed further into 1H27. Together, these studies should provide important insight into the role of TROP2 ADCs in NSCLC and help shape subsequent clinical development strategies. AstraZeneca’s investment in Summit and collaboration to evaluate ADCs with ivonescimab supports the ADC plus PD-(L)1/VEGF strategy. Meanwhile, Kelun Biotech’s positive OptiTROP-Lung05/-Lung06 readouts underpin sac-TMT’s activity in 1L NSCLC across PD-L1 spectrum and MSD’s global developments.
Trodelvy validates TROP2 ADC adoption with ASCENT-GYN as the next near-term read-across for sac-TMT. Trodelvy’s strong commercial momentum continues to validate the TROP2 ADC class. Sales reached US$506mn in 3Q26, up 42% YoY and 11% QoQ, bringing the annualized run rate to US$2.0bn, with growth driven by 1L TNBC and 3L+ HR+/HER2- breast cancer. Ph3 ASCENT-GYN data in EC, expected by end-2026, will offer an important read-across to sac-TMT’s positive global TroFuse-005 data. Gilead also plans to evaluate Trodelvy plus BioNTech’s pumitamig (PD-L1×VEGF-A) in 1L TNBC.
Sac-TMT combines global validation with lifecycle optionality. TroFuse-005 is the first positive global Ph3 study of sac-TMT and supported FDA priority review in EC (PDUFA date of 15 Jun 2027). Beyond EC, multiple global Ph3 trials are ongoing in NSCLC, while MSD is planning additional global Ph3 trials of sac-TMT in combination with either Keytruda or MK-2010 (PD-1/VEGF bsAb) in 1L NSCLC. With multiple global Ph3 readouts expected across 2027–28, we believe sac-TMT is well positioned to evolve into a multi-tumor global franchise as MSD’s cornerstone asset.
Maintain BUY. Datroway’s later readout schedule in 1L NSCLC warrants close attention, while Trodelvy’s strong commercial trajectory provides increasing proof of class adoption. Near-term watchpoints include the ASCENT-GYN readout around end-2026, the sac-TMT EC approval, further TroFuse Ph3 readouts in 2027 and initiation of MK-2010 plus sac-TMT Ph3 combinations in 1H27. Factoring in the smooth development of sac-TMT, we raise our DCF-based TP from HK$642.29 to HK$645.62 (WACC 8.69%, terminal growth rate 3.5%).
Attention on Datroway’s multiple Ph3 readouts in 1L NSCLC in 1H27, while sac- TMT is building differentiated evidence from China. AstraZeneca has announced an equity investment in Summit Therapeutics, together with clinical collaborations to evaluate ivonescimab (PD-1/VEGF bsAb) in combination with ADCs including Datroway. This underscores the strategic importance of ADC plus PD-(L)1/VEGF bsAb combinations. In NSCLC, with its earlier setback in 2L+ NSCLC vs docetaxel, Datroway is currently approved only for TKI-pretreated EGFR-mutant disease. The AVANZAR readout in 1L TROP2-positive NSCLC has been pushed further into 1H27, while four Ph3 readouts are expected in 1H27, including three in 1L NSCLC—AVANZAR in 1L TROP2-positive NSCLC, and TROPION-Lung07/-Lung08 in 1L PD-L1 <50% and ≥50% NSCLC, respectively—and one in 2L EGFR-mutant NSCLC in combination with osimertinib (TROPION-Lung15). Together, these studies should provide important insight into the role of TROP2 ADCs in first-line NSCLC and help shape subsequent clinical development strategies. Two additional Datroway Ph3 readouts in TNBC are expected in 2H27. Nevertheless, sac-TMT has already delivered two positive China Ph3 readouts in 1L NSCLC: OptiTROP-Lung05 in PD-L1-positive disease and OptiTROPLung06 in PD-L1-negative disease. Together, these results support sac-TMT’s activity across the PD-L1 spectrum and provide a strong clinical foundation for MSD’s global development program.
Trodelvy validates TROP2 ADC adoption with ASCENT-GYN as the next near-term read-across for sac-TMT. Trodelvy sales reached US$506mn in 3Q26, up 42% YoY and 11% QoQ, bringing 9M26 sales to US$896mn and annualized run rate to US$2bn. Growth was driven by continued uptake in 1L TNBC and 3L+ HR+/HER2- breast cancer (BC) across both the US and Europe, reinforcing the view that TROP2 ADCs can evolve into a treatment backbone in these settings. Given sac-TMT’s stronger efficacy in these indications—notably a PFS HR of 0.35 with sac-TMT versus 0.66 for Trodelvy in 3L+ HR+/HER2- BC—we remain constructive on sac-TMT’s long-term commercial potential. Gilead also plans to evaluate Trodelvy plus BioNTech’s pumitamig (PD-L1×VEGF-A) in 1L TNBC. In EC, Trodelvy’s Ph3 ASCENT-GYN study in EC is expected to read out around end-2026. This will provide an important read-across to sac-TMT’s global TroFuse-005 results, which already showed robust Ph3 PFS and OS benefits in 2L+ EC (mPFS 7.2 vs 3.9 months, HR 0.59; mOS 19.0 vs 12.1 months, HR 0.68).
Sac-TMT combines global validation with a broad and accelerating development program. TroFuse-005 is the first positive global Ph3 study from sac-TMT’s expansive TroFuse program and the first global Ph3 of a TROP2 ADC to improve outcomes in EC. The FDA has accepted the EC NDA for priority review, with a PDUFA date of 15 Jun 2027. Beyond EC, multiple global Ph3 trials are ongoing in NSCLC, including studies in 1L PD-L1-high NSCLC and 1L sq-NSCLC maintenance. MSD is also planning additional global Ph3 trials of sac-TMT in combination with either Keytruda or MK-2010 (PD- 1/VEGF bsAb) in 1L NSCLC. Following constructive discussions with the FDA, Ph3 development of MK-2010 in combination with sac-TMT, which is currently in Ph2, is expected to begin in 1H27. We view this as a significant strategic step in the emerging ADC + PD-(L)1/VEGF bispecific landscape. Sac-TMT is also entering its harvest season, with multiple global Ph3 readouts expected in 2027, covering 3L+ gastric cancer, 3L EGFR-m NSCLC and 1L post-CDK4/6 HR+/HER2- BC. Readouts in 1L PD-L1-high NSCLC, 2L EGFR-m NSCLC and 2L cervical cancer could follow in 2028. In our view, as a cornerstone asset for MSD, sac-TMT’s steady stream of clinical readouts and expanding global development footprint support its evolution into a multi-tumor franchise.